export const mockBlogPosts = [
    {
        id: '1',
        slug: 'navigating-fda-guidance-gene-therapy-2025',
        title: 'Navigating New FDA Guidelines for Gene Therapy Approvals: A 2025 Outlook',
        excerpt: 'The FDA has recently updated its framework for gene therapy products, emphasizing long-term safety monitoring and manufacturing consistency. Here is what biotech sponsors need to know to prevent clinical holds.',
        content: 'The landscape of gene therapy regulation is shifting rapidly as the FDA adapts to the unique challenges of durable treatments. In its latest guidance, the agency has placed renewed emphasis on Chemistry, Manufacturing, and Controls (CMC) as a critical bottleneck for approval. Sponsors are now expected to demonstrate potency assay validation much earlier in the clinical development lifecycle than previously required.\n\nFurthermore, the long-term follow-up requirements have been clarified, with a risk-based approach allowing for some flexibility in the duration of monitoring. This change is significant for developers of non-integrating viral vectors, who may now face reduced post-market surveillance burdens compared to integrating vector therapies. Our analysis suggests that proactive engagement with the CBER office during the pre-IND phase is more critical than ever to align on these surrogate endpoints.\n\nFor companies targeting rare diseases, the "Consultation for Clinical Studies of Orphan Drugs" program remains an underutilized pathway. By leveraging real-world evidence (RWE) to supplement small clinical trial cohorts, sponsors can robustly demonstrate efficacy. Mevoq has successfully guided three gene therapy candidates through this accelerated pathway in the last 18 months.',
        category: 'Regulatory Strategy',
        tags: ['FDA', 'Gene Therapy', 'CMC', 'Clinical Trials', 'Orphan Drugs'],
        featured_image: 'https://placehold.co/1200x630/001F3F/FFF?text=Gene+Therapy+Guidelines',
        author: 'Dr. Sarah Chen',
        author_role: 'Senior Regulatory Consultant',
        published: true,
        published_at: '2025-10-15T09:00:00Z',
        updated_at: '2025-10-15T09:00:00Z'
    },
    {
        id: '2',
        slug: 'avoiding-clinical-holds-ind-submissions',
        title: 'Top 5 Reasons for FDA Clinical Holds on IND Submissions in 2025',
        excerpt: 'Clinical holds can delay drug development by months or years. We analyze the most common triggers for FDA holds in the current regulatory climate and how to avoid them.',
        content: 'An FDA clinical hold is a sponsor’s worst nightmare, immediately halting all study activities. Our review of 2025 enforcement actions reveals that insufficient toxicology data remains the number one cause of full clinical holds. Specifically, the FDA is increasingly scrutinizing the relevance of animal models in relation to human dose selection, particularly for biologics.\n\nSecondly, Investigator Brochures (IB) that fail to clearly communicate risk mitigation strategies are a frequent sticking point. The agency expects a transparent summary of all safety signals, not just a data dump of preclinical results. Quality of the drug substance is the third major factor; impurities that are not adequately characterized or qualified according to ICH Q3 guidelines will trigger an immediate red flag.\n\nIt is worth noting that "partial holds" are becoming a more common regulatory tool, allowing some arms of a trial to proceed while others are paused. While less devastating than a full hold, they still signal a lack of confidence from the review division. To mitigate this risk, Mevoq recommends a rigorous mock-audit of the entire IND package prior to submission, simulating the FDA review process to catch these gaps early.',
        category: 'Compliance',
        tags: ['IND', 'FDA', 'Clinical Holds', 'Toxicology', 'Risk Management'],
        featured_image: 'https://placehold.co/1200x630/0052CC/FFF?text=Clinical+Holds',
        author: 'Dr. Ashok Shah',
        author_role: 'Founder & Chief Regulatory Officer',
        published: true,
        published_at: '2025-09-22T14:30:00Z',
        updated_at: '2025-09-22T14:30:00Z'
    },
    {
        id: '3',
        slug: 'ectd-4-0-implementation-timeline',
        title: 'Preparing for eCTD v4.0: Mandatory Implementation Timelines',
        excerpt: 'The transition to eCTD v4.0 is approaching. Learn about the new bidirectional communication features and how to upgrade your submission publishing systems.',
        content: 'Electronic Common Technical Document (eCTD) version 4.0 represents the most significant update to submission standards in over a decade. Unlike v3.2.2, which was largely a one-way street from sponsor to agency, v4.0 enables two-way communication. This allows health authorities to send queries and requests for information (RFIs) directly within the submission sequence hierarchy, greatly streamlining the review lifecycle.\n\nSponsors must be aware that the implementation timelines differ by region. The FDA is currently in a voluntary pilot phase, with mandatory adoption expected for certain submission types by late 2026. The EMA and PMDA (Japan) are following similar but slightly staggered schedules. A key technical change is the move from XML to HL7 FHIR standards, requiring significant updates to publishing software.\n\nWaiting until the deadline is a risky strategy. We advise clients to run a pilot submission using v4.0 standards for a minor amendment or annual report well before the mandatory cutoff. This "soft launch" approach allows your regulatory operations team to troubleshoot validation errors without jeopardizing a critical NDA or BLA approvals path.',
        category: 'FDA Updates',
        tags: ['eCTD', 'Regulatory Operations', 'Submissions', 'FDA', 'EMA'],
        featured_image: 'https://placehold.co/1200x630/1DD1A1/001F3F?text=eCTD+v4.0',
        author: 'Michael Torres',
        author_role: 'Director of Regulatory Operations',
        published: true,
        published_at: '2025-08-10T11:15:00Z',
        updated_at: '2025-08-10T11:15:00Z'
    },
    {
        id: '4',
        slug: 'orphan-drug-designation-benefits',
        title: 'Maximizing the Benefits of Orphan Drug Designation',
        excerpt: 'Beyond tax credits, Orphan Drug Designation offers strategic advantages including seven years of market exclusivity. Here is how to construct a winning ODD application.',
        content: 'Securing Orphan Drug Designation (ODD) is a pivotal milestone for biotechs developing treatments for rare diseases (defined in the US as affecting fewer than 200,000 people). The financial incentives are well-known: a 25% tax credit on clinical research costs and waiver of the PDUFA user fee (worth over $3 million).\n\nHowever, the strategic benefits often outweigh the financial ones. Seven years of market exclusivity upon approval provides a powerful shield against generic competition, which is crucial for maximizing ROI on niche therapies. Additionally, the designation opens doors for increased regulatory assistance from the Office of Orphan Products Development (OOPD). \n\nThe key to a successful ODD application lies in the "plausible hypothesis." You do not need to prove efficacy at this stage, but you must demonstrate a scientific rationale for why the drug is likely to be effective in the specific rare disease. Mevoq specializes in drafting these rationales, leveraging mechanism-of-action data to build a compelling case even with limited clinical evidence.',
        category: 'Regulatory Strategy',
        tags: ['Orphan Drugs', 'Market Exclusivity', 'Rare Disease', 'FDA'],
        featured_image: 'https://placehold.co/1200x630/003BA3/FFF?text=Orphan+Drug+Designation',
        author: 'Dr. Sarah Chen',
        author_role: 'Senior Regulatory Consultant',
        published: true,
        published_at: '2025-07-05T08:45:00Z',
        updated_at: '2025-07-05T08:45:00Z'
    },
    {
        id: '5',
        slug: 'case-study-accelerated-approval-oncology',
        title: 'Case Study: Achieving Accelerated Approval for a Novel Oncology Agent',
        excerpt: 'How Mevoq helped a mid-sized pharma client secure FDA Accelerated Approval using a surrogate endpoint, shaving 3 years off their development timeline.',
        content: 'In 2024, Mevoq partnered with a client developing a novel targeted therapy for metastatic non-small cell lung cancer (NSCLC). The standard approval pathway would have required overall survival (OS) data, necessitating a trial duration of 5+ years. Our strategy focused on validating Objective Response Rate (ORR) as a surrogate endpoint reasonably likely to predict clinical benefit.\n\nWe facilitated three Critical Path Innovation Meetings (CPIM) with the FDA to align on the statistical analysis plan for the single-arm Phase 2 trial. By demonstrating the high correlation between ORR and OS in historical control data, we secured the agency’s agreement to accept the surrogate endpoint.\n\nThe result was an NDA submission 36 months earlier than originally projected. The drug received Accelerated Approval, allowing the client to generate revenue while confirming clinical benefit in a post-marketing confirmatory trial. This case highlights the value of aggressive, scientifically-backed regulatory negotiation.',
        category: 'Case Studies',
        tags: ['Oncology', 'Accelerated Approval', 'Case Study', 'Clinical Strategy'],
        featured_image: 'https://placehold.co/1200x630/001F3F/1DD1A1?text=Oncology+Case+Study',
        author: 'Dr. Ashok Shah',
        author_role: 'Founder & Chief Regulatory Officer',
        published: true,
        published_at: '2025-06-12T10:00:00Z',
        updated_at: '2025-06-12T10:00:00Z'
    },
    {
        id: '6',
        slug: 'post-approval-compliance-checklist',
        title: 'The Essential Post-Approval Compliance Checklist for NDA Holders',
        excerpt: 'Approval is just the beginning. Maintain your license and avoid warning letters with this comprehensive checklist for CMC changes and Annual Reports.',
        content: 'Receiving an NDA approval letter is a moment of triumph, but it immediately triggers a new set of obligations. Many sponsors, especially smaller ones, underestimate the rigor of post-marketing requirements (PMRs) and commitments (PMCs). Failure to meet these milestones can result in public "Failure to Respond" letters or even withdrawal of approval.\n\nPrimary compliance focus areas must include the Annual Report (due within 60 days of the approval anniversary), quarterly safety reports (PADERs or PSURs), and strict adherence to the drug advertising and promotion regulations (OPDP). CMC changes are another frequent pitfall; sponsors must correctly categorize changes as CBE-0, CBE-30, or Prior Approval Supplements (PAS) based on risk.\n\nMevoq provides a "Compliance Watch" service that manages this entire lifecycle. We recently helped a client remediate a backlog of overdue Annual Reports, successfully negotiating with the FDA to avoid a Warning Letter by demonstrating a corrected and robust quality system.',
        category: 'Compliance',
        tags: ['Post-Marketing', 'Compliance', 'CMC', 'Pharmacovigilance'],
        featured_image: 'https://placehold.co/1200x630/4CAF50/FFF?text=Compliance+Checklist',
        author: 'Mr. Manish Purohit',
        author_role: 'VP Quality & Compliance',
        published: true,
        published_at: '2025-05-20T13:20:00Z',
        updated_at: '2025-05-20T13:20:00Z'
    }
];

export const mockServices = [
    {
        id: '1',
        title: "Regulatory Strategy & Planning",
        description: "Navigate complex regulatory pathways with confidence. We design optimal strategies for global market access.",
        icon: "map-pin",
        featured_image: "https://images.unsplash.com/photo-1454165804606-c3d57bc86b40?w=1200&q=80",
        features: [
            "Regulatory pathway assessment",
            "Meeting preparation (FDA, EMA, PMDA)",
            "Risk mitigation strategies",
            "Global harmonization planning",
            "Labeling & artwork",
            "Technical file preparations",
            "Clinical evaluation reports"
        ],
        slug: "regulatory-strategy-planning",
        content: `
<h2>Strategic Regulatory Planning</h2>
<p>Our regulatory strategy services are designed to provide a clear roadmap from discovery to commercialization. We help you navigate the complex web of global regulations to ensure your product reaches the market as efficiently as possible.</p>

<p>With over a decade of experience working with pharmaceutical companies across the globe, our team understands the nuances of regulatory requirements in different markets. We partner with you from the earliest stages of development to ensure regulatory considerations are built into your product strategy from day one.</p>

<h3>Key Offerings</h3>
<ul>
    <li>
        <strong>Pathway Assessment:</strong> We analyze your product's characteristics to determine the most appropriate regulatory pathway (e.g., NDA, BLA, 505(b)(2), MAA). Our experts evaluate the competitive landscape and regulatory precedents to recommend the most efficient path forward.
    </li>
    <li>
        <strong>Gap Analysis:</strong> We identify potential gaps in your data package and recommend strategies to address them before submission. This proactive approach minimizes the risk of Complete Response Letters and accelerates approval timelines.
    </li>
    <li>
        <strong>Meeting Preparation:</strong> We prepare you for critical meetings with health authorities, including Pre-IND, End-of-Phase 2, and Pre-NDA/BLA meetings. Our team develops comprehensive briefing documents and anticipates agency questions.
    </li>
    <li>
        <strong>Global Harmonization:</strong> We develop synchronized strategies for multi-regional submissions, leveraging ICH guidelines and mutual recognition agreements to reduce redundant work.
    </li>
</ul>

<h3>Our Process</h3>
<p>We begin every engagement with a comprehensive assessment of your current regulatory position. This includes a review of existing data, competitive intelligence gathering, and stakeholder interviews. From this foundation, we develop a tailored strategy that aligns with your business objectives and timeline.</p>

<p>Our regulatory strategists work as an extension of your team, providing ongoing guidance and adapting strategies as your program evolves. We believe in transparent communication and regular milestone reviews to ensure alignment throughout the development process.</p>

<h3>Why Choose Mevoq?</h3>
<p>Our team brings diverse experience from pharmaceutical companies, consulting firms, and regulatory agencies. This unique perspective allows us to anticipate regulatory challenges and develop creative solutions that keep your program on track.</p>

<p>We pride ourselves on building long-term partnerships with our clients. Many of our engagements have spanned multiple product approvals, demonstrating the trust and value we bring to every relationship.</p>
`,
        case_study_snippet: "Helped biotech company achieve FDA breakthrough designation"
    },
    {
        id: '2',
        title: "Regulatory Documentation",
        description: "Expert preparation of submission-ready regulatory documents that meet global standards.",
        icon: "file-text",
        featured_image: "https://images.unsplash.com/photo-1450101499163-c8848c66ca85?w=1200&q=80",
        features: [
            "Global DMF & ASMF Management",
            "CEP (EDQM) Submissions",
            "CADIFA (ANVISA) Compliance",
            "CTD/eCTD Compilation",
            "IND/NDA/BLA Preparation",
            "Annual reports and updates"
        ],
        slug: "regulatory-documentation",
        content: `
<h2>Expert Regulatory Documentation</h2>
<p>High-quality documentation is the foundation of a successful regulatory submission. Our team of expert writers and regulatory professionals ensures that your documents are clear, concise, and compliant with all applicable guidelines.</p>

<p>We understand that regulatory submissions must meet rigorous standards while clearly communicating the safety and efficacy of your product. Our documentation services span the entire product lifecycle, from initial development through post-approval maintenance.</p>

<h3>Document Types</h3>
<ul>
    <li><strong>INDs/CTAs:</strong> Investigational New Drug applications and Clinical Trial Applications that enable you to begin clinical studies.</li>
    <li><strong>NDAs/BLAs/MAAs:</strong> Marketing applications for US and EU markets, prepared in full compliance with current guidance.</li>
    <li><strong>Investigator Brochures:</strong> Comprehensive summaries of clinical and nonclinical data that investigators need to conduct trials safely.</li>
    <li><strong>Briefing Books:</strong> Strategic briefing documents for health authority meetings that frame discussions favorably.</li>
</ul>

<h3>Core Expertise & Specialized Filings</h3>
<p>Our deep technical expertise lies in the preparation and management of complex global dossiers for active substances and finished products. We specialize in:</p>
<ul>
    <li><strong>DMFs (Drug Master Files):</strong> Complete preparation and lifecycle management of US and Global Drug Master Files (Type II, III, IV, V), ensuring full compliance with FDA technical and administrative requirements.</li>
    <li><strong>ASMFs (Active Substance Master Files):</strong> Expert drafting of Open and Restricted parts for European submissions, facilitating seamless coordination between manufacturers and marketing authorization holders.</li>
    <li><strong>CEPs (Certificates of Suitability):</strong> Navigating the EDQM procedure to obtain and maintain Certificates of Suitability to the Monographs of the European Pharmacopoeia, ensuring your APIs meet rigorous EU quality standards.</li>
    <li><strong>CADIFA (ANVISA Support):</strong> Specialized support for the Certification of Suitability of Active Pharmaceutical Ingredients in Brazil, managing the complex documentation required by ANVISA for market entry.</li>
</ul>

<h3>Our Documentation Process</h3>
<p>Every project begins with a detailed kickoff meeting to understand your product, timeline, and specific requirements. We develop a documentation plan that outlines deliverables, milestones, and review cycles.</p>

<p>Our writers work from templates aligned with FDA, EMA, and ICH guidelines. We maintain consistency across modules and sections, ensuring a cohesive submission that facilitates efficient agency review.</p>

<h3>Quality Assurance</h3>
<p>All documents undergo multiple rounds of quality control before delivery. We verify scientific accuracy, regulatory compliance, and editorial consistency. Our QC process includes hyperlink verification, cross-reference checking, and format validation.</p>

<p>We also provide publishing services for eCTD submissions, ensuring your electronic dossiers are technically valid and viewer-ready.</p>
`,
        case_study_snippet: "Created complete NDA package in 4 months vs. industry average of 8"
    },
    {
        id: '3',
        title: "Quality & Compliance",
        description: "Build robust quality systems that pass inspections and ensure sustainable compliance.",
        icon: "shield-check",
        featured_image: "https://images.unsplash.com/photo-1507003211169-0a1dd7228f2d?w=1200&q=80",
        features: [
            "Quality system design & remediation",
            "GMP/GCP compliance audits",
            "Inspection readiness",
            "CAPA effectiveness review",
            "Vendor qualification"
        ],
        slug: "quality-compliance",
        content: `
<h2>Quality Systems & Compliance</h2>
<p>A robust quality system is essential for maintaining compliance and ensuring patient safety. We help you build and maintain quality management systems (QMS) that meet the highest standards of the FDA, EMA, and other global regulators.</p>

<p>In today's regulatory environment, quality is not just a requirement—it's a competitive advantage. Companies with strong quality cultures experience fewer deviations, faster approvals, and greater stakeholder confidence.</p>

<h3>Our Compliance Services</h3>
<ul>
    <li><strong>QMS Design & Implementation:</strong> We build QMS tailored to your company's size and stage of development, from startup to multinational enterprise.</li>
    <li><strong>Audits:</strong> We conduct mock inspections and vendor audits to identify and remediate compliance risks before regulators do.</li>
    <li><strong>Inspection Readiness:</strong> We prepare your team for regulatory inspections through training, mock interviews, and facility walkthroughs.</li>
    <li><strong>CAPA Management:</strong> We help you develop effective corrective and preventive action systems that address root causes.</li>
    <li><strong>Vendor Qualification:</strong> We assess and qualify suppliers and contract manufacturers to ensure your supply chain meets GMP standards.</li>
</ul>

<h3>Inspection Support</h3>
<p>When inspections occur, our team can provide on-site support. We help coordinate document requests, coach subject matter experts, and advise on responses to observations.</p>

<p>After inspections, we assist with response preparation, ensuring your commitments are achievable and your remediation plans are comprehensive.</p>

<h3>Continuous Improvement</h3>
<p>Our goal is to help you build a culture of quality that supports long-term commercial success. We implement metrics and monitoring systems that drive continuous improvement and demonstrate compliance to regulators and business partners alike.</p>
`,
        case_study_snippet: "Successful GMP inspections by regulatory authorities for our clients"
    },
    {
        id: '4',
        title: "Medical & Scientific Writing",
        description: "Clear, compelling regulatory narratives that accelerate review and approval.",
        icon: "pen-tool",
        featured_image: "https://images.unsplash.com/photo-1456324504439-367cee3b3c32?w=1200&q=80",
        features: [
            "Clinical study reports",
            "Regulatory responses",
            "Scientific publications",
            "Patient-facing materials",
            "Expert reports"
        ],
        slug: "medical-scientific-writing",
        content: `
<h2>Medical & Scientific Writing</h2>
<p>Clear communication of scientific data is critical for regulatory success. Our medical writers combine scientific expertise with regulatory knowledge to create compelling narratives that support your product's value proposition.</p>

<p>We believe that great regulatory writing is invisible—it allows the data to speak for itself while guiding the reviewer to understand the significance of your findings. Our writers have backgrounds in life sciences, medicine, and regulatory affairs.</p>

<h3>Writing Services</h3>
<ul>
    <li><strong>Clinical Study Reports (CSRs):</strong> Comprehensive reports of clinical trial data that meet ICH E3 guidelines and agency expectations.</li>
    <li><strong>Clinical Summaries & Overviews:</strong> High-level summaries for Module 2 of marketing applications that synthesize years of development.</li>
    <li><strong>Safety Narratives:</strong> Detailed descriptions of adverse events that provide context for safety assessments.</li>
    <li><strong>Manuscripts & Abstracts:</strong> Publications for peer-reviewed journals and conference presentations that support your regulatory and commercial goals.</li>
    <li><strong>Patient-Facing Materials:</strong> Informed consent forms, patient information leaflets, and educational materials in clear, accessible language.</li>
</ul>

<h3>Our Writing Approach</h3>
<p>We work closely with your clinical and scientific teams to ensure that your data is presented accurately and persuasively. Every document begins with a detailed outline and messaging strategy that aligns with your overall regulatory approach.</p>

<p>We use structured authoring tools and maintain style guides to ensure consistency across documents and therapeutic areas. Our writers are trained in data visualization best practices, creating tables and figures that communicate complex information clearly.</p>

<h3>Regulatory Response Support</h3>
<p>When health authorities request additional information, time is critical. Our writers are experienced in developing responses that address agency questions directly while maintaining consistency with your original submission.</p>
`,
        case_study_snippet: "Successfully addressed the queries raised by ethics committee"
    },
    {
        id: '5',
        title: "Risk Management",
        description: "Proactive identification and mitigation of regulatory and quality risks.",
        icon: "alert-triangle",
        featured_image: "https://images.unsplash.com/photo-1460925895917-afdab827c52f?w=1200&q=80",
        features: [
            "Risk assessments",
            "Gap analysis",
            "Deviation investigation",
            "Change control evaluation",
            "Safety signal management"
        ],
        slug: "risk-management",
        content: `
<h2>Risk Management Strategies</h2>
<p>Proactive risk management is a regulatory expectation and a business necessity. We help you identify, assess, and mitigate risks throughout the product lifecycle, from development through post-marketing surveillance.</p>

<p>Effective risk management protects patients, preserves asset value, and demonstrates to regulators that you take safety seriously. Our approach combines systematic assessment methods with deep industry experience.</p>

<h3>Risk Management Activities</h3>
<ul>
    <li><strong>Risk Management Plans (RMPs):</strong> Comprehensive plans for identifying and minimizing risks, required for EU marketing authorizations and increasingly expected globally.</li>
    <li><strong>REMS:</strong> Risk Evaluation and Mitigation Strategies for high-risk products that balance access with safety.</li>
    <li><strong>Signal Detection:</strong> Ongoing monitoring of safety data to identify potential safety signals before they become regulatory issues.</li>
    <li><strong>Benefit-Risk Assessments:</strong> Structured frameworks for evaluating and communicating the benefit-risk balance of your products.</li>
    <li><strong>Pharmacovigilance Planning:</strong> Systems and processes for monitoring safety throughout the product lifecycle.</li>
</ul>

<h3>Deviation & Change Control</h3>
<p>Manufacturing deviations and process changes can introduce new risks. Our experts help you investigate root causes, assess impact, and implement effective corrective actions.</p>

<p>We also support change control processes, ensuring that changes are properly evaluated and documented before implementation.</p>

<h3>Impurity Assessments</h3>
<p>Elemental impurities, nitrosamines, and other potentially harmful substances require specialized expertise. We help you assess risks and develop control strategies that meet current regulatory expectations.</p>
`,
        case_study_snippet: "Successful vendor approval through nitrosamine impurities compliance"
    },
    {
        id: '6',
        title: "Administrative Support",
        description: "Streamline your compliance operations with expert administrative assistance.",
        icon: "folder",
        featured_image: "https://images.unsplash.com/photo-1586281380349-632531db7ed4?w=1200&q=80",
        features: [
            "Process optimization",
            "US authorized agent",
            "US FDA administrative activities",
            "Accreditation certification applications",
            "Submission tracking"
        ],
        slug: "administrative-support",
        content: `
<h2>Administrative & Operational Support</h2>
<p>Regulatory operations involves a myriad of administrative tasks that can drain your team's resources. We provide efficient support to keep your regulatory department running smoothly, allowing your experts to focus on strategic activities.</p>

<p>Whether you need help with day-to-day operations or support for a major submission, our administrative team delivers reliable, high-quality assistance.</p>

<h3>Support Services</h3>
<ul>
    <li><strong>Submission Publishing:</strong> Electronic publishing of eCTD submissions, including validation, hyperlinking, and technical QC.</li>
    <li><strong>Document Management:</strong> Organization and archiving of regulatory records in compliance with 21 CFR Part 11 and other requirements.</li>
    <li><strong>Project Management:</strong> Tracking of regulatory timelines and deliverables to keep your programs on schedule.</li>
    <li><strong>US Agent Services:</strong> Acting as your US agent for FDA communications, receiving correspondence and forwarding it promptly.</li>
    <li><strong>Regulatory Intelligence:</strong> Monitoring of regulatory developments and guidance documents that affect your products.</li>
</ul>

<h3>Process Optimization</h3>
<p>We help you streamline regulatory workflows and implement best practices that increase efficiency. This includes template development, procedure optimization, and technology recommendations.</p>

<h3>Scalable Support</h3>
<p>Our support model is flexible and scalable. You can engage us for specific projects or ongoing operational support. We adapt to your needs, ramping up for major milestones and maintaining a steady presence during quieter periods.</p>

<p>We handle the details so you can focus on strategy and science. Our goal is to be a seamless extension of your team, providing reliable support that you can count on.</p>
`,
        case_study_snippet: "Reduced administrative burden by 60% for mid-size pharma"
    }
];

export const mockTestimonials = [
    {
        id: '1',
        name: "Dr. Sarah Chen",
        role: "VP Regulatory Affairs",
        company: "BioGenix Therapeutics",
        content: "Mevoq cut our FDA submission timeline by 40%. Their expertise in regulatory strategy is unmatched. We launched 3 months ahead of schedule.",
        rating: 5
    },
    {
        id: '2',
        name: "Marcus Williams",
        role: "Chief Scientific Officer",
        company: "PharmaTech Solutions",
        content: "The team's deep regulatory knowledge and proactive approach saved us from costly compliance issues. Best consulting investment we've made.",
        rating: 5
    },
    {
        id: '3',
        name: "Dr. Amelia Rodriguez",
        role: "Director of Quality",
        company: "MedLife Innovations",
        content: "Working with Mevoq felt like having an extension of our own team. Their documentation expertise is exceptional.",
        rating: 5
    }
];

export const mockTeam = [
    {
        id: '1',
        name: "Dr. Ashok Shah",
        role: "Founder & Chief Regulatory Officer",
        bio: "Regulatory expert with 15+ years in pharmaceutical regulation. Led 200+ successful drug approvals.",
        expertise: ["FDA Strategy", "CMC Review", "DMFs, ASMFs, CEPs & CADIFA", "IND/NDA Submissions"],
        avatar_url: null
    },
    {
        id: '2',
        name: "Mr. Manish Purohit",
        role: "VP Quality & Compliance",
        bio: "Quality systems expert with Big Pharma and biotech experience. Specializes in remediation and inspection readiness.",
        expertise: ["Quality Systems", "GMP Compliance", "Inspection Management"],
        avatar_url: null
    },
    {
        id: '3',
        name: "Mr. Shailesh Shah",
        role: "Director of Regulatory Writing",
        bio: "Medical writer and regulatory affairs specialist. Authored regulatory documents for 50+ global submissions.",
        expertise: ["Medical Writing", "Regulatory Documentation", "Global Submissions"],
        avatar_url: null
    }
];

export const mockStats = {
    successful_submissions: 50,
    project_weeks_saved: 500,
    years_experience: 11,
    countries_served: 15
};
